ArticleEuropean heart journal. Case reports2026
TENDYNE mitral valve implantation complicated by heparin-induced thrombocytopenia in a patient with NSCLC: a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter mitral valve replacement (TMVR) is an emerging therapeutic option [SA1.1] for patients with complex mitral valve disease who are at high surgical risk. The TENDYNE transcatheter mitral valve system enables treatment in anatomically challenging cases but may be associated with early device thrombosis prior to endothelialization. We report a complex cardio-oncology case of a 52-year-old man with severe combined mitral valve disease and concomitant potentially curable non-small cell lung cancer who underwent TMVR following induction chemo-immunotherapy to optimize oncologic timing. Case summary: The early postoperative course was complicated by heparin-induced thrombocytopenia (HIT) type II, resulting in progressive thrombosis of the left atrium and prosthetic valve despite therapeutic anticoagulation with argatroban. Imaging demonstrated significant prosthetic obstruction requiring urgent surgical thrombectomy, explantation of the transcatheter valve, and bioprosthetic mitral valve replacement. After multidisciplinary perioperative management, including tailored anticoagulation strategies, the patient recovered and was discharged in stable condition. Discussion: This case highlights the interplay between TMVR-associated thrombogenicity, HIT-driven hypercoagulability, and the complexity of treatment sequencing in cardio-oncology patients, emphasizing the importance of individualized, interdisciplinary decision-making.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.